1997 related articles for article (PubMed ID: 20465361)
1. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
Candiotti KA; Gitlin MC
Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
[TBL] [Abstract][Full Text] [Related]
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
3. Tapentadol hydrochloride: a centrally acting oral analgesic.
Wade WE; Spruill WJ
Clin Ther; 2009 Dec; 31(12):2804-18. PubMed ID: 20110020
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of side effects of prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and/or antidepressant therapy in chronic non-cancer pain.
Manchikanti L; Manchikanti KN; Pampati V; Cash KA
Pain Physician; 2009; 12(1):259-67. PubMed ID: 19165308
[TBL] [Abstract][Full Text] [Related]
5. Opioids: a two-faced Janus.
Ahlbeck K
Curr Med Res Opin; 2011 Feb; 27(2):439-48. PubMed ID: 21194392
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
Afilalo M; Morlion B
Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
[TBL] [Abstract][Full Text] [Related]
7. Tapentadol immediate release for the relief of moderate-to-severe acute pain.
Hartrick CT
Expert Opin Pharmacother; 2009 Nov; 10(16):2687-96. PubMed ID: 19795998
[TBL] [Abstract][Full Text] [Related]
8. Opioid and adjuvant analgesics: compared and contrasted.
Khan MI; Walsh D; Brito-Dellan N
Am J Hosp Palliat Care; 2011 Aug; 28(5):378-83. PubMed ID: 21622486
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
10. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties.
Tzschentke TM; Christoph T; Kögel B; Schiene K; Hennies HH; Englberger W; Haurand M; Jahnel U; Cremers TI; Friderichs E; De Vry J
J Pharmacol Exp Ther; 2007 Oct; 323(1):265-76. PubMed ID: 17656655
[TBL] [Abstract][Full Text] [Related]
11. Opioid tolerance and dependence: an inevitable consequence of chronic treatment?
Adriaensen H; Vissers K; Noorduin H; Meert T
Acta Anaesthesiol Belg; 2003; 54(1):37-47. PubMed ID: 12703345
[TBL] [Abstract][Full Text] [Related]
12. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians' (ASIPP) Guidelines.
Trescot AM; Helm S; Hansen H; Benyamin R; Glaser SE; Adlaka R; Patel S; Manchikanti L
Pain Physician; 2008 Mar; 11(2 Suppl):S5-S62. PubMed ID: 18443640
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
[TBL] [Abstract][Full Text] [Related]
14. Opioid use by patients in an orthopedics spine clinic.
Mahowald ML; Singh JA; Majeski P
Arthritis Rheum; 2005 Jan; 52(1):312-21. PubMed ID: 15641058
[TBL] [Abstract][Full Text] [Related]
15. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study.
Kleinert R; Lange C; Steup A; Black P; Goldberg J; Desjardins P
Anesth Analg; 2008 Dec; 107(6):2048-55. PubMed ID: 19020157
[TBL] [Abstract][Full Text] [Related]
16. Codeine and oxycodone use in patients with chronic rheumatic disease pain.
Ytterberg SR; Mahowald ML; Woods SR
Arthritis Rheum; 1998 Sep; 41(9):1603-12. PubMed ID: 9751092
[TBL] [Abstract][Full Text] [Related]
17. Addiction to opioids in chronic pain patients: a literature review.
Højsted J; Sjøgren P
Eur J Pain; 2007 Jul; 11(5):490-518. PubMed ID: 17070082
[TBL] [Abstract][Full Text] [Related]
18. Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain.
Labianca R; Sarzi-Puttini P; Zuccaro SM; Cherubino P; Vellucci R; Fornasari D
Clin Drug Investig; 2012 Feb; 32 Suppl 1():53-63. PubMed ID: 23389876
[TBL] [Abstract][Full Text] [Related]
19. Tapentadol extended release for chronic pain patients.
Taylor R; Pergolizzi JV; Raffa RB
Adv Ther; 2013 Jan; 30(1):14-27. PubMed ID: 23328938
[TBL] [Abstract][Full Text] [Related]
20. Opioid analgesia: perspectives on right use and utility.
Ballantyne JC
Pain Physician; 2007 May; 10(3):479-91. PubMed ID: 17525783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
